Insilico Medicine � Target X Inhibitor (Fibrotic diseases treatment)

This drug is a small molecule inhibitor of Target X, a novel target proposed by Insilico Medicine’s AI target discovery engine platform PandaOmics for fibrotic diseases. The drug demonstrated robust in vitro and in vivo efficacy in inhibiting inflammation, myofibroblast activation, and fibrotic-related tissue remodeling. Its use could potentially treat idiopathic pulmonary fibrosis and kidney fibrosis.